Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress Biotech Investing
Health Canada Approves AbbVie's RINVOQ® for the Treatment of Adults with Active Psoriatic Arthritis Biotech Investing
Results From Phase 2 CodeBreaK 100 Show LUMAKRAS Is The First And Only KRAS G12C Inhibitor With Overall Survival Data Biotech Investing
Kite's Tecartus® Demonstrates High Response Rate in Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Earning Priority Review Designation Biotech Investing
Results from IMBRUVICA® RESONATE-2 Study Provide Up to Seven Years of Progression-Free and Overall Survival Data in First-Line Chronic Lymphocytic Leukemia Biotech Investing
Phase 2 Fight Trial Continues To Show Improved Overall Survival With Bemarituzumab Plus Chemotherapy In Patients With FGFR2b+ Gastric And Gastroesophageal Cancers Biotech Investing
Trodelvy® Demonstrates Superior Outcomes to Standard of Care in Second-Line Treatment of Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study Biotech Investing
Bristol Myers Squibb to Take Part in Goldman Sachs 42nd Annual Global Healthcare Conference Biotech Investing
